O Shaughnessy Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN

O Shaughnessy Asset Management LLC raised its position in shares of Astrazeneca Plc (NYSE:AZN) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 331,384 shares of the company’s stock after buying an additional 43,082 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Astrazeneca were worth $58,158,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Triumph Capital Management purchased a new position in Astrazeneca during the third quarter valued at $25,000. Bangor Savings Bank lifted its position in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new position in Astrazeneca during the fourth quarter valued at $30,000. YANKCOM Partnership purchased a new position in Astrazeneca during the fourth quarter valued at $31,000. Finally, TFC Financial Management Inc. lifted its position in Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after buying an additional 335 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

AZN opened at $186.06 on Monday. The stock has a 50-day moving average price of $190.84 and a 200-day moving average price of $185.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a market cap of $288.57 billion, a PE ratio of 27.94, a P/E/G ratio of 1.59 and a beta of 0.25. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Sell-side analysts predict that Astrazeneca Plc will post 9.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.